Argenica Therapeutics Ltd · ASX:AGN
Argenica Therapeutics — Investor Presentation (October 2021)
16 slides from Argenica Therapeutics's investor presentation, October 2021
Slide 1: Argenica Therapeutics
ARGENICA THERAPEUTICS OCTOBER 2021 1 www.argenica.com.au
Slide 2: Disclaimer
This presentation has been prepared by Argenica Therapeutics Limited and its related entities (the “Company”) and is not an offer document. It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You shoul
Slide 3: Granted Patents
ARGENICA THERAPEUTICS GRANTED PATENTS Granted in the EU, Japan Commercialise “best in class” Neuroprotective peptide and China, and a US national novel neuroprotective that could offer protection to filing in progress. therapeutics to reduce brain the brain following stroke and cell death following
Slide 4: Share structure and capital summary
Total Shares on issue 73,172,250 Other Shareholders ARGENICA THERAPEUTICS Inventors and Research Team Shares subject to escrow for 12 months 1 3,322,500 SHAREHOLDERS 7 Shares subject to escrow for 24 months 2 22,625,752 4.7% 5.4% 3.7% 19% 21% 47% Options on issue (escrow for 24 months) 2 & 3 8,300,0
Slide 5: How It Works / Applications
HOW IT WORKS APPLICATIONS Cell death in the brain, or infarction, results from inadequate blood supply to the affected area. ISCHEMIC STROKE EXAMPLE STROKE Initial infarction sets off a cascade ARGENICA THERAPEUTICS ARG-007 has shown significant efficacy in of cell death. a number of animal models o
Slide 6: Stroke burden and lack of neuroprotective drugs
15 MILLION PEOPLE ONLY LOW RECOVERY 10 PERCENT WILL RATE DUE TO BRAIN HAVE A STROKE RECOVER ALMOST EACH YEAR1 COMPLETELY 3 CELL DAMAGE ARGENICA THERAPEUTICS One in four people will have Long term disability Stroke attacks 1.9 million a stroke in their lifetime2 brain cells per minute4 Lasting brain
Slide 7: Current stroke treatment pathway
Rapidly increasing level of Long term cell damage impacts neural cell death and damage patient outcomes and recovery ARGENICA THERAPEUTICS IN-FIELD TREATMENT REHAB HOSPITAL TRIAGE PLAN Patient in ambulance and 1-4 weeks acute arrives at emergency Diagnose type of stroke Current therapeutic hospitali
Slide 8: Reduction in neural cell death and recovery time
Reduction in Reduction in neural cell death patient recovery and damage time ARGENICA THERAPEUTICS IN-FIELD TREATMENT REHAB HOSPITAL TRIAGE PLAN Patient in ambulance and 1-4 weeks acute arrives at emergency Diagnose type of stroke Current therapeutic hospitalisation1 followed by treatment intensive
Slide 9: Potential benefits of ARG-007
Simple injection for paramedics to Extends the treatment window for use in emergency stroke scenarios stroke patients who have to travel significant distance for treatment ARGENICA THERAPEUTICS Protects the brain against the Reduces special care requirements and damaging effects of stroke intensive
Slide 10: Preclinical efficacy and safety findings
REDUCES BRAIN POTENTIAL TO SAFE WITH NO TISSUE DEATH ADMINISTER IN ADVERSE EFFECTS THE FIELD ARGENICA THERAPEUTICS Pre-clinical studies showed ARG-007 No adverse effects were ARG-007 showed a 67% does not exacerbate bleeding in observed in a PK animal study, reduction in brain tissue hemorrhagic str
Slide 11: Pre-clinical and Phase 1 timeline
ARGENICA THERAPEUTICS Completion of preliminary study activities, including clinical site management setup, preparation of ethics submission and healthy volunteer patient recruitment. ANIMAL STUDY ANIMAL STUDY IN-HUMAN STUDY Determines how is Characterise the safety profile of absorbed, distributed,
Slide 12: Phase 1 trial objectives
1. IMPROVE THE OF HOW EFFECTS THE BODY ARGENICA THERAPEUTICS 2. EVALUATE THE WHEN ADMINISTERED 3. DETERMINE THE 12 4. IDENTIFY ANY POSSIBLE www.argenica.com.au
Slide 13: Path to Phase 2 and other indications
Data collected from the Phase 1 clinical trial will be critical to progress into Phase 2 trials, where will be administered to stroke patients. While stroke is the current corporate and commercial focus, ARGENICA THERAPEUTICS safety data from the Phase 1 clinical trial can potentially be used to mov
Slide 14: Board and management
Geoff Pocock Dr Liz Dallimore Non-Executive Chairman CEO • 20 years’ experience in commercialisation of emerging • Over 20 years' experience in R&D, technology technologies and capital markets commercialisation and management consulting, including • Non-Executive Director of EMVision Medical Devices
Slide 15: Investment highlights
3# PRE-CLINICAL DATA Positive pre-clinical results provide encouraging dataset leading into in-human trials. ARGENICA THERAPEUTICS 1# CLEAR PATHWAY TO TRIALS 2# 4# 5# Clear clinical pathway and EXCEPTIONAL NEAR TERM robust capital position to UNMET CLINICAL NEED TEAM CATALYSIS execute Phase 1 clinic
Slide 16: Contact
ARGENICA THERAPEUTICS For further information please contact: Dr Liz Dallimore CEO E: info@argenica.com.au 16 www.argenica.com.au
Argenica Therapeutics — Investor Presentation (October 2021) on 6ix